Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)

OBJECTIVES: To confirm the effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab in patients with rheumatoid arthritis (RA) in a setting close to real-life medical care in Germany. METHODS: A multicentre open-label phase IIIb study was undertaken. Patients with active RA with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Burmester, Gerd R, Feist, E, Kellner, H, Braun, J, Iking-Konert, C, Rubbert-Roth, A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2010
Gaiak:
Clinical and Epidemiological Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3070275/
https://ncbi.nlm.nih.gov/pubmed/21187298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2010.139725
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak